Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

68Ga-NeoBOMB1 and 68Ga-PSMA R2 PET/MRI in the Evaluation of Patients With Biochemical Recurrence of Prostate Cancer

NCT03698370 is registered in ClinicalTrials.gov with Andrei Iagaru as lead sponsor.

NCT NCT03698370
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03698370 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
68Ga-NeoBOMB1 and 68Ga-PSMA R2 PET/MRI in the Evaluation of Patients With Biochemical Recurrence of Prostate Cancer
Lead sponsor
Andrei Iagaru
Phase
Phase 2
Overall status
Completed
Start date
December 15, 2020
Completion date
February 11, 2022
Enrollment
27 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

prostate adenocarcinoma, psa progression, recurrent prostate carcinoma